Tesla sued by 25 California counties over hazardous waste handling
Tesla allegedly mishandled hazardous waste for years throughout the state of California according to a lawsuit filed by district attorneys in 25 counties there.
House passes an expanded child tax credit bill and sends it to the Senate
It’s unclear whether the bill can pass the Senate, where some members want changes and GOP Sen. Chuck Grassley said he’s worried it would make President Joe Biden “look good.”
Meta, X, TikTok, Snap and Discord face growing appetite in Congress for tighter social media regulation
Wall Street doesn’t seem worried the tech firms will take significant financial hits to their businesses from Congress.
Qualcomm earnings beat estimates as smartphone chip sales suggest recovery
Under CEO Cristiano Amon, Qualcomm has been working to apply its chip technology to markets beyond smartphones.
Fed holds rates steady, indicates it is not ready to start cutting
The Federal Reserve on Wednesday sent a tepid signal that it is done raising interest rates but made it clear that it is not ready to start cutting.
Here’s what changed in the new Fed statement
This is a comparison of Wednesday’s Federal Open Market Committee statement with the one issued after the Fed’s previous policymaking meeting in December.
Federal Reserve holds interest rates steady, sets the stage for cuts. What that means for your money
As the Federal Reserve sets the stage for rate cuts later this year, here’s what that means for your credit card, mortgage rate, auto loan and savings account.
A look at how stocks perform before and after the Fed’s first rate cut — and how it may be different this time
History shows that stocks typically rally after the Federal Reserve starts to lower rates, but the way that plays out exactly can get more complicated.
Meta’s continued rally could hinge on the fortunes of upstart retailers Temu and Shein
Online retailers Temu and Shein, which are both based in the China region, helped contribute to Meta’s ad rebound in 2023.
Biogen drops controversial Alzheimer’s drug Aduhelm to focus on Leqembi, experimental treatments
Biogen said its decision to drop Aduhelm, which had a polarizing approval and launch, was “not related to any safety or efficacy concerns.”
